VEGFB and diabetic kidney disease: Although Chisquared test showed no significant differences in the usage of RAS inhibitors, SGLT2 inhibitors and statins between eGFR≥ 90 mL/min/1.73m2 group and eGFR<90 mL/min/1.73m2 group, which sharpens our observations, future studies designed in cohorts are still required to confirm the findings and to determine the role of VEGF-B in DKD pathology as well as whether serum VEGF-B level could be used for early prediction of DKD or NADKD.